WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Exelixis earnings were $521.3M for the trailing 12 months ending Dec 31, 2024, with 176.9% growth year over year. The latest EXEL earnings report on Dec 31, 2024 announced Q4 2024 earnings of $139.9M, up 18.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EXEL reported annual earnings of $521.3M, with 150.9% growth. The next EXEL earnings date is Apr 28, 2025.

EXEL past earnings growth

How has EXEL's earnings growth performed historically?

Company
176.92%
Industry
11.8%
Market
63.03%
EXEL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
EXEL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
EXEL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

EXEL earnings history

Current Revenue
$2.2B
Current Earnings
$521.3M
Current Profit Margin
24%

EXEL Return on Equity

Current Company
23.8%
Current Industry
-2%
Current Market
34.1%
EXEL's Return on Equity (23.8%)... subscribe to Premium to read more.
High Return on Equity Performance

EXEL undefined

Current Company
18.2%
Current Industry
-0.4%
EXEL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when EXEL announces earnings.

EXEL undefined

Current Company
26.79%
Current Industry
5.9%
EXEL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EXEL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
EXEL$737.90M$521.27M+11.17%$1.80
ASND-$266.15M-$393.84MN/A-$6.80
MRNA-$3.42B-$3.56BN/A-$9.28
INCY$408.16M$32.62M-40.13%$0.16
BMRN$650.86M$426.86M-16.91%$2.25
View Top Biotech Stocks

EXEL earnings dates

Next earnings date
Apr 28, 2025

Exelixis Earnings Reports & History FAQ

What were Exelixis's earnings last quarter?

On EXEL's earnings call on Invalid Date, Exelixis (NASDAQ: EXEL) reported Q4 2024 earnings per share (EPS) of $0.49, up 81.48% year over year. Total EXEL earnings for the quarter were $139.86 million. In the same quarter last year, Exelixis's earnings per share (EPS) was $0.27.

If you're new to stock investing, here's how to buy Exelixis stock.

When does Exelixis report earnings?

The next EXEL earnings call is Invalid Date. Add EXEL to your watchlist to be reminded of Exelixis's next earnings date.

What was EXEL's earnings growth in the past year?

As of Exelixis's earnings date in Invalid Date, Exelixis's earnings has grown 176.92% year over year. This is 165.12 percentage points higher than the US Biotechnology industry earnings growth rate of 11.8%. EXEL earnings in the past year totalled $521.27 million.

Is Exelixis profitable or losing money?

As of the last Exelixis earnings report, Exelixis is currently profitable. Exelixis's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $521.27 million, a 150.89% increase year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.